We analyzed predictive factors for the outcome of 113 acute myeloid leukemia patients receiving reduced-intensity conditioning prior to allogeneic hematopoietic stem cell transplantation (HSCT). Patients were ineligible for conventional-intensity HSCT. Conditioning consisted of fludarabine and 50% of the conventional dose of busulfan (n ¼ 93) or total body irradiation (n ¼ 20). The source of stem cells was blood in 102 patients, marrow in 10, and both in one. In total, 50 (44.2%) donors were HLAmatched siblings, 50 (44.2%) unrelated fully matched and 13 (11.5%) partially mismatched family (n ¼ 1) or unrelated (n ¼ 12) donors. In all, 107 (94.6%) patients showed neutrophil and platelet engraftment after a median time of 13.5 and 13 days. The probabilities of event-free survival (EFS) (median follow-up: 12 months) were 49% for patients with less than 5% blasts in the marrow, 24% for patients with 5-20% blasts (P ¼ 0.002) and 14% with 420% blasts (Pp0.001). Death occurred because of relapse in 29 patients (25.6%), infection in 12 patients (10.6%), acute graft-versus-host disease in eight patients (7.0%) and organ toxicity in nine patients (7.9%). In multivariate analysis, higher number of blasts in the marrow, alternative donors and low Karnofsky performance score were independent adverse prognostic factors for EFS.
Summary:
We analyzed predictive factors for the outcome of 113 acute myeloid leukemia patients receiving reduced-intensity conditioning prior to allogeneic hematopoietic stem cell transplantation (HSCT). Patients were ineligible for conventional-intensity HSCT. Conditioning consisted of fludarabine and 50% of the conventional dose of busulfan (n ¼ 93) or total body irradiation (n ¼ 20). The source of stem cells was blood in 102 patients, marrow in 10, and both in one. In total, 50 (44.2%) donors were HLAmatched siblings, 50 (44.2%) unrelated fully matched and 13 (11.5%) partially mismatched family (n ¼ 1) or unrelated (n ¼ 12) donors. In all, 107 (94.6%) patients showed neutrophil and platelet engraftment after a median time of 13.5 and 13 days. The probabilities of event-free survival (EFS) (median follow-up: 12 months) were 49% for patients with less than 5% blasts in the marrow, 24% for patients with 5-20% blasts (P ¼ 0.002) and 14% with 420% blasts (Pp0.001). Death occurred because of relapse in 29 patients (25.6%), infection in 12 patients (10.6%), acute graft-versus-host disease in eight patients (7.0%) and organ toxicity in nine patients (7.9%). In multivariate analysis, higher number of blasts in the marrow, alternative donors and low Karnofsky performance score were independent adverse prognostic factors for EFS. Bone Marrow Transplantation (2003) 31, 1089-1095. doi:10.1038/sj.bmt.1704062
Keywords: acute myeloid leukemia; reduced conditioning; allogeneic stem cell transplantation For adult patients with newly diagnosed acute myeloid leukemia (AML) up to an age of 60 years, progress in therapy and supportive care has led to gradual improvement in the overall survival (OS). 1, 2 Postinduction therapy in patients with AML includes allogeneic hematopoietic stem cell transplantation (HSCT) for those having a suitable donor, offering up to 50% disease-free survival 3 Nonrelapse mortality (NRM) is a persistent problem in allogeneic stem cell transplantation, mainly because of toxicity induced by the conditioning regimen and acute or chronic graft-versus-host disease (GvHD). 4 Intensification of chemotherapy or an increase of the dose of total body irradiation (TBI) reduced the relapse rate, 5 but did not translate into improved survival because of a higher NRM. 6 Owing to serious comorbidity like previous infection and impaired organ function, the arbitrary age limit for intensive conditioning therapy in patients with AML is between 50 and 55 years. Nevertheless, the median age of AML is between 65 and 70 years. 7 Therefore, most patients with AML are not eligible for conventional allogeneic transplant procedures. Reduced-intensity conditioning therapy for allogeneic HSCT offers the benefit of graft-versus-leukemia effects with a better safety profile. 8, 9 Modified pretransplant regimens range from low-dose single-fraction TBI and enhanced transplant immunosuppression 10 to protocols containing purine analogs 11 and alkylating agents like busulfan, melphalan or thiotepa. 12, 13 The cytotoxic regimens can be combined with antithymocyte globulin (ATG) 14 or alemtuzumab 15 in order to reduce the risk for GvHD. There is limited information on the clinical efficacy of reduced-intensity conditioning in a large cohort of patients with AML. We report a retrospective analysis of 113 patients with AML having a suitable donor, but were considered to have unacceptable risk of morbidity and mortality and therefore not eligible for conventional allogeneic transplantation.
Patients and methods

Patients
The patient's characteristics are summarized in Table 1 . Between February 1998 and December 2000, 113 patients with AML from 10 German transplant centers underwent allogeneic HSCT after reduced-intensity conditioning therapy and were reported to the cooperative German transplant group. In the second transplant group (n ¼ 8) the same donor was used in six patients. In all, 29 patients (25.7%) had a Karnofsky performance status p70% prior to transplantation. CMV serostatus was available for 87 donor and recipient pairs. In 24 cases, anti-CMV IgG was negative for donor and recipient, positive for both in 27 cases, positive/negative and negative/positive in 18 cases each, respectively. Disease status and patients' characteristics are summarized in Table 2 . Partial remission (PR) of AML was defined as blast reduction up to 20% in the marrow following chemotherapy. The percentage of bone marrow blasts determined by light microscopy was available for 104 of the 113 patients prior to conditioning. For this study there was no central pathology review, but criteria for disease status were identical for all patients. The nine patients for whom the blast percentage was not known were excluded for that analysis. The Karnofsky performance status was evaluated at each center prior to start of conditioning therapy. Supportive therapy was accomplished according to local procedures. Treatment protocols were approved by the institutional review boards of each participating center and written informed consent of individual risk adapted therapy was obtained from all patients.
Conditioning regimen
The conditioning protocols are summarized in Table 3 . A total of 93 patients (82.3%) received fludarabine 90 to 
Graft characteristics
Donor selection was performed according to the published German consensus recommendations. 16 Serologic typing was performed for HLA-A, B and C. HLA-DRB1 and DQB1 loci were analyzed by high-resolution DNA-based typing. In the unrelated setting, only one DRB1/DQB1 subclass or one class I mismatch was accepted. In total, 50 patients (44.2%) received HLA-matched grafts from family donors, 50 patients (44.2%) received grafts from HLAmatched unrelated donors. One patient (0.9%) had an HLA-nonidentical family donor and 12 patients (10.6%) had HLA-nonidentical unrelated donors. The median age of donors was 43 years (range 16-75). In 28 cases (24.8%), the recipient/donor relation was male to female. The median number of CD34+ cells infused was 5.5 Â 10 6 /kg (range 0.95-30.0), the total number of CD3+ cells was 3.06 Â 10 8 /kg (range 0.001-10.40). The grafts consisted of peripheral blood stem cells (PBSC) in 102 cases (90.3%), bone marrow (BM) in 10 (8.8%) cases and both in one (0.9%). Four grafts were CD34+ selected. Prophylactic donor lymphocyte infusions were administered in 13 patients (11.1%) after a median period of 65 (range 14-125) days after transplantation. A total of 51% of all patients (n ¼ 58) received G-CSF s.c. or i.v. at a dose of 5 mg/kg/day starting on day +1 to +6 until an absolute neutrophil count of more than 1.0 Â 10 9 /l was achieved for 3 days. The median duration of G-CSF support was 9 (range 1-46) days.
GvHD prophylaxis
GvHD prophylaxis consisted of cyclosporine (CsA) alone (n ¼ 46), CsA and methotrexate (MTX) (n ¼ 22), CsA and steroids (n ¼ 3), CsA and mycophenolate mofetil (MMF) (n ¼ 40) and CsA/MTX/steroids in one patient. GvHDprophylaxis was not used in one patient who had received CD34+ selected peripheral blood stem cells. In 79 patients (67.5%) ATG was given as part of the conditioning regimen.
Statistical analysis
OS, freedom from relapse, and event-free survival (EFS) were calculated according to the method of Kaplan and Meier. 17 The Log-Rank test was performed to analyze the impact of different factors on EFS. Cox proportional hazards regression was performed to test for the prognostic role of those factors that had achieved a P-value of 0.2 or less in the Log-Rank test: Karnofsky performance status, acute GvHD, unrelated vs related donor, disease-status and number of marrow blasts.
Results
Engraftment
In total, 111 patients (94.6%) showed myeloid engraftment, defined as neutrophils 40.5 Â 10 9 /l after a median of 13.5 (range 0-35) days. Platelet recovery 420 Â 10 6 /ml was achieved after 13 (range 0-370) days. Six patients (5.1%) had no engraftment. All were in relapse (n ¼ 4) or refractory (n ¼ 2) to chemotherapy, five had received PBSC and one patient BM. Their grafts were unmanipulated with 44 Â 10 6 CD34+ cells from matched unrelated (n ¼ 4), matched sibling (n ¼ 1) or mismatched unrelated (n ¼ 1) donors. Two of them had received TBI/fludarabine and four busulfan/fludarabine.
Acute and chronic GvHD
The probability of acute GvHD XGrade II until day 100 was 42% (n ¼ 46) (Figure 1 ) with no significant differences between recipients of related and unrelated grafts. Grade III and IV GvHD was observed in 17 (15%) and 13 (11.5%) patients, respectively. Chronic GvHD occurred in 35 (32.7%) out of 107 patients at risk after day 100. Of these, 28 (26.2%) patients showed signs of limited chronic GvHD and seven (6.5%) of extensive chronic GvHD at the time of analysis. Table 3 Conditioning 
Survival analysis
OS and EFS are projected to be 32 and 29% at 24 months after a median observation time of 12 months (range 46-937 days) for patients alive (Figure 2) . Figure 3 shows a superior EFS at 24 months for patients in first complete remission (CR) compared to those with subsequent CP, PR, relapsing or refractory disease. The probability of EFS for first CR patients at 24 months is 52%. Event is defined as any cause of death including relapse. The strongest predictor for EFS in 104 analyzed patients is the number of blasts in the marrow prior to transplantation (Figure 4) . GvHD-prophylaxis with cyclosporine alone (n ¼ 40) vs others (n ¼ 64) had no influence on OS.
Factors predictive for EFS
Univariate analysis demonstrated that neither CD34+ nor CD3+ cell-dose was associated with differences in EFS. EFS showed to be significantly better in the univariate analysis in recipients of grafts from related donors (39.9%) than in those receiving HSC from unrelated donors (16.7%, P ¼ 0.028).
No statistical significance for EFS was achieved in univariate analysis for age (above or below the median of 51 years), cytogenetic risk group (P ¼ 0.5), use of ATG and use of TBI. The univariate analysis is provided in Table 5 . In addition, there was no difference for EFS between the low number of BM patients (n ¼ 10) and the PBSC group. Cox proportional hazards regression analysis showed number of blasts in the marrow before transplant o5%/ 5-20%/420% (RR 2.143, CI 1.420-3.232, Pp0.001), the donor source related/unrelated (RR 1.853 CI 1.034-3.321, P ¼ 0.038) and the Karnofsky performance status p70 (RR 0.555, CI 0.303-1.016, P ¼ 0.056) to be independent prognostic factors for EFS (Table 6 ). Others n =54 Probability of event-free survival (remission status prior conditioning) (n =113) (1-2) P = 0.0020 (1-3) P <0.0001 (2-3) P = 0.0726
Probability of event-free survival (number of blasts prior conditioning) (n =104) Figure 4 Probability of EFS according to marrow blasts prior conditioning. 
Toxicity
Nonrelapse mortality of the procedure after 24 months was 53% for the entire group of patients. Patients in CR and PR had a significantly lower probability of treatmentrelated mortality (33%) compared to patients with advanced disease (66%, P ¼ 0.029). During the first 100 days, the NRM-rate was 12 and 30% in the two groups, respectively ( Figure 5 ). The causes of death and the number of relapses are summarized in Table 4 . The nonrelapse mortality was higher in the unrelated in comparison to the related group (P ¼ 0.002).
Discussion
This retrospective analysis of 113 AML patients not eligible for conventional conditioning pretreatment and allogeneic transplantation confirms the potential of reduced-intensity conditioning to induce rapid and sustained engraftment. It is the first report on the results of a comparably large group of patients with AML receiving reduced-intensity conditioning prior to allogeneic transplantation either with related or unrelated donors. The EFS showed an inverse correlation with disease status immediately prior to transplantation, similarly to what is known from standard conditioning therapy in larger cohorts of AML patients. 18, 19 Recent data indicate that postremission therapy with cytarabine prior to allogeneic transplantation for AML in first CR is not associated with improved outcome compared to upfront allogeneic transplantation after successful induction therapy. 20 Whether this holds true for reducedintensity conditioning has to be demonstrated in prospective trials. However, this retrospective analysis demonstrates that only patients who achieve a significant clearance of leukemic blasts by either induction or salvage therapy benefit from reduced-intensity conditioning. Our data are consistent when first CR or the number of blasts in the marrow as predictive factors are used. Although the impact of morphological assessment of BM smears is limited by a wide interobserver variability, it is still one of the most important methods to define disease status and consider further therapy options in AML.
The fact that the results of transplantation of grafts from unrelated donors were inferior to those achieved with related donors in our analysis may reflect the increased risk of disease progression for those patients for whom an unrelated donor was searched while further or no further treatment was performed. When adjusting for disease status and other factors, this difference was still statistically significant. In addition, the increased risk for therapyrelated mortality should be emphasized. Nevertheless, this observation is already known for conventional transplantation in acute leukemia, and stresses the need for fast search programs to identify optimal matched donors for patients without matched siblings as soon as possible.
The use of PBSC has been shown to be associated with a better disease-free survival compared to BM in one large prospective study. 21 The fact that almost all patients have received PBSC might therefore explain why our small subgroup of PR patients seems to benefit significantly from the procedure with seven out of 17 patients being alive and disease-free after a median follow-up of 12 months. The higher number of T and NK cells contained in PBSC might be advantageous to induce stable donor chimerism and sustained engraftment in patients after reduced-intensity conditioning. 22 This might even be more relevant for patients receiving minimal conditioning before allogeneic transplantation. 10 The protocols used in this study have been shown to induce early complete donor chimerism, especially in patients with acute leukemia following prior chemotherapy. 23 Another important finding is the fact that patients with higher leukemic burden by the time of transplantation have an increased risk for treatment-related mortality compared to patients in CR or PR. The increased risk for late deaths in patients with advanced acute leukemia has been shown in large retrospective studies, 24 and might either be associated with the efforts of the treating physicians to stop immunosuppression earlier in high-risk patients rendering them at risk for GvHD, or by the increased risk of infectious complications and organ toxicity in these immunocompromised patients. 25 Although the day 100 mortality can be further reduced by using a merely immunoablative regimen with 2 Gy TBI and low-dose fludarabine, 10 a longer follow-up of these studies, also including unrelated donors, will show whether these achievements will translate into improved long-term survival rates.
The fact that a Karnofsky performance status of greater than 70, comparable with the modification performance status-scale 2 of the Eastern Cooperative Oncology Group (ECOG), is an independent factor for survival highlights the fact that reduced-intensity conditioning cannot compensate for the cumulative toxicity of acute and chronic GvHD and therefore still requires an adequate performance status.
In our population of AML-patients, the OS remains acceptable given that all centers considered their patients as poor candidates for conventional conditioning because of age or concurrent medical conditions. Of course, we cannot preclude that patient selection differed between the centers, and that some patients with good performance status might have also be treated with conventional conditioning therapy. The definition of what is eligible or not eligible for myeloablative regimens remains variable and needs to be defined with more accuracy in future studies. Most of the published data with reduced-intensity conditioning regimens included various malignant hematological diseases in their analysis and suffer from the same constraints. [10] [11] [12] [13] [14] 26 In most of those phase I or II trials, the authors included indolent or aggressive lymphoma, Hodgkin's disease and multiple myeloma in addition to acute leukemia and myelodysplastic syndromes. Their analyses showed durable engraftment, clinical or molecular remissions and more or less reduced nonrelapse mortality.
Randomized trials comparing standard conditioning therapy with reduced-intensity protocols in AML patients are about to start and will define the role of this new treatment strategy in a prospective manner. 27 In conclusion, our data show that reduced-intensity conditioning and allogeneic transplantation of hematopoietic stem cells can induce stable remission in older AML patients with significant comorbidities. On the other hand, patients with either refractory or relapsing disease with more than 20% blasts in the marrow or reduced performance status seem to be poor candidates for this procedure. As the selection of postremission therapy is limited in this older patient population, further efforts are needed to determine the best postinduction therapy and define the role of dose reduced conditioning and allogeneic hematopoietic stem cell transplantation.
